Work for an Organization that brings innovative therapies to patients worldwide.
VectorY combines the potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for disease areas of high unmet medical need.
Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics.
With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody gene therapy platform. Product candidates are based on next generation vector technologies, which will enable a proprietary and highly scalable manufacturing process within VectorY’s own manufacturing facilities.
Short description of the department Vector Development
The Assay Development department is an essential part of VectorY as they are responsible for the development and execution of assays for baculovirus and AAV batch characterization throughout the whole company. The Assays are divided in molecular, analytical and (pre)clinical assays, each having their focus and technical specialty. The group utilizes the molecular toolbox to analyse AAV vectors with novel characteristics. Furthermore, the group is responsible for development of de novo assays for which are used by all other VectorY teams for further development.